Abstract: The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.

Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.

Abstract: A quick-assembly structure includes an inserting portion and an inserting port allowing the inserting portion to be inserted, where one of the inserting portion and the inserting port is provided on the chassis, and the other one is provided on the back frame. A locking block of the inserting portion is movably arranged relative to the inserting port; and in an assembled state, a bump of the inserting portion is inserted into the inserting port along with the inserting portion, the locking block is pushed by an elastic force of an elastic member of the inserting port to enter a locking position, and at the locking position, a locking end of the locking block enters the inserting port and abuts against an abutting surface of the bump so as to restrict the inserting portion from being pulled out in a direction opposite to an inserting direction thereof.

Abstract: A quick-assembly structure includes first inserting connection structures, where each of the first inserting connection structures includes an inserting and clamping member and a groove body; each of the groove bodies includes an inserting groove and a clamping groove which are in communication with each other, the corresponding inserting and clamping member is inserted into the inserting groove in a vertical direction and then horizontally slides into the clamping groove in a first direction; and the seat cushion is further provided with elastic buckles, the chassis includes a clamping connection surface, and when the inserting and clamping members slide to predetermined positions in the clamping grooves, the elastic buckles are clamped with the clamping connection surface of the chassis in an abutting manner so as to restrict the chassis from sliding relative to the seat cushion in a direction opposite to the first direction.

Abstract: A wireless power transmitter can include a wireless power transfer coil designed to magnetically couple with a corresponding coil in a wireless power receiver to facilitate wireless power transfer from the wireless power transmitter to the wireless power receiver, a power converter configured to drive the wireless power transfer coil, and control and communications circuitry coupled to the wireless power transfer coil and the power converter. The control and communications circuitry can be configured to operate the power converter to drive the wireless power transfer coil so as to transfer power to the wireless power receiver in accordance with a negotiated power transfer. Simultaneously during power transfer, the control and communications circuitry can send a polling signal to detect a foreign object including a wireless transponder and reduce or stop wireless power transfer upon receiving a response to the polling signal from a foreign object including a wireless transponder.

Abstract: The present disclosure provides a thermal insulation apparatus and a crucible production device. The thermal insulation apparatus is configured for supporting a mold, and includes: a housing, a first flange, a second flange and a plurality of reinforcing members, and the housing, the first flange and the second flange are coaxially arranged. An inner wall of the housing is enclosed to form an accommodating cavity, and the accommodating cavity is configured for accommodating the mold; a water-cooling cavity is enclosed between the inner wall and an outer wall of the housing; the first flange is connected to a top portion of the housing, so as to fix an upper edge of the mold to the top portion of the housing; the second flange is connected to a bottom portion of the housing; and the plurality of reinforcing members are arranged between the bottom portion of housing and second flange.

Abstract: A needling device includes: a needling assembly, a support, a base and a bearing frame. The base is provided inside the bearing frame, and the base is for bearing the preform body. The support is provided with a guide rail. The needling assembly is slidably connected to the support, and may slide along the guide rail, to needle the preform body. The needling assembly may perform an all-around needling operation to the circular-arc surface of the preform body, and depth and density of the needling by the needling assembly to the circular-arc surface of the preform body are even, which may prevent deformation and layering of the preform body during the deposition, to improve the processing quality of the preform body.

Abstract: Provided are a vapor injection device and a compressor. The vapor injection device includes an injector valve plate, an injector plate, and an injector reed valve. One side of the injector plate facing toward the injector valve plate is provided with an avoidance groove. A guide post is disposed protruding from one side of the injector plate facing away from the injector valve plate. The guide post is inserted into a fixed scroll of the compressor and provided with an injection channel. A vapor injection inlet cavity is formed between the rear housing, the injector valve plate, and the fixed scroll. The injector reed valve is disposed between the injector valve plate and the injector plate and attaches to the injector valve plate, the injector reed valve is provided with a movable sheet, and the movable sheet, the injector valve plate and the avoidance groove form a one-way valve structure.

Abstract: The present invention relates to compounds of the formula and the pharmaceutically acceptable salts and esters thereof, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show antiproliferative activity and may be especially useful for the treatment of cancer.

Abstract: The present invention provides compounds according to formula I having the designations provided herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

Abstract: The present invention provides compounds according to formula I and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity

Abstract: Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

Abstract: The present invention provides compounds having formula (II): wherein X, n, R1–R12 are defined herein, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (II) and a pharmaceutically acceptable carrier or excipient. The invention further provides a method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound represented by formula (II).

Abstract: The present invention provides compounds having formula (I): and formula (II): wherein X, n, and R1-R12 are defined herein, or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound represented by formula (I) or (II) and a pharmaceutically acceptable carrier or excipient. The invention further provides a method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound represented by formula (I) or (II).

Abstract: The present invention provides compounds according to formula I and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

Abstract: The present invention provides compounds according to formula I 1

Abstract: The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

Abstract: The present invention provides compounds having formula (I): 1

Abstract: The present invention provides compounds according to formula I and formula II and pharmaceutically acceptable salts and esters thereof, having the designations provided herein and which inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity.

Abstract: Disclosed are novel pyrimido compounds that are selective inhibitors of both KDR an FGFR kinases and are selective against LCK. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon, lung and prostate tumors. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.